

May 13, 2008

Astellas Announces Acquisition of Treasury Stocks

(Acquisition of treasury stocks pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, May 13, 2008 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted acquisition of treasury stocks pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of treasury stocks
In order to improve capital efficiency and enhance return to shareholders.

2. Contents of acquisition
 - (1) Class of shares subject to be acquired: Common stock of the Company
 - (2) Total number of shares to be possibly acquired:
9.1 million shares (maximum)
(The percentage compared to the total number of shares outstanding: 1.82%)
 - (3) Aggregate amount of acquisition cost: 40 billion yen (maximum)
 - (4) Period of acquisition: From May 15, 2008 to June 20, 2008

(Reference)

The status of treasury stocks as of March 31, 2008:

Total number of shares outstanding: 498,083,535 shares

Number of treasury stocks: 20,881,100 shares

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com